Information Provided By: 
Fly News Breaks for February 3, 2016
GILD
Feb 3, 2016 | 07:39 EDT
Baird said Gilead delivered another top and bottom-line beat, driven by Japanese Hep C sales. The firm noted Hep C sales in the U.S. missed expectations but the company's guidance reflects its confidence in the franchise's durability. Baird said Gilead's bottom-line makes it look like a value stock and reiterated its Outperform rating and $135 on the shares.
News For GILD From the Last 2 Days
There are no results for your query GILD
